Evidence map›Paper›PMID 27303288›Full record

ReviewFrontiers in aging neuroscience2016

A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects.

Yan Shen, Jinsha Huang, Ling Liu, Xiaoyun Xu, Chao Han, Guoxin Zhang, Haiyang Jiang, Jie Li, Zhicheng Lin, Nian Xiong and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in aging neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Non-human primate models of PD to test novel therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2018
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Yan ShenDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Jinsha HuangDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Ling LiuDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Xiaoyun XuDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Chao HanDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Guoxin ZhangDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Haiyang JiangDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Jie LiDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Zhicheng LinDepartment of Psychiatry, Harvard Medical School, Division of Alcohol and Drug Abuse, and Mailman Neuroscience Research Center, McLean Hospital Belmont, MA, USA.
Nian XiongDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Tao WangDepartment of Neurology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology Wuhan, China.
Union Hospital · CNHuazhong University of Science and Technology · CNHarvard University · US

Funding

Human dopamine transporter gene: variations and transcriptional regulationR01DA021409 · NIDA · MCLEAN HOSPITAL · PI LIN, ZHICHENG CARL · 2007 to 2024
$4.9M
NIDA NIH HHS R01 DA021409
6 · The paper itself

Abstract

Parkinson's Disease (PD) is a progressively neurodegenerative disorder, implicitly characterized by a stepwise loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) and explicitly marked by bradykinesia, rigidity, resting tremor and postural instability. Currently, therapeutic approaches available are mainly palliative strategies, including L-3,4-dihydroxy-phenylalanine (L-DOPA) replacement therapy, DA receptor agonist and deep brain stimulation (DBS) procedures. As the disease proceeds, however, the pharmacotherapeutic efficacy is inevitably worn off, worse still, implicated by side effects of motor response oscillations as well as L-DOPA induced dyskinesia (LID). Therefore, the frustrating status above has propeled the shift to cell replacement therapy (CRT), a promising restorative therapy intending to secure a long-lasting relief of patients' symptoms. By far, stem cell lines of multifarious origins have been established, which can be further categorized into embryonic stem cells (ESCs), neural stem cells (NSCs), induced neural stem cells (iNSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). In this review, we intend to present a compendium of preparation and application of multifarious stem cells, especially in relation to PD research and therapy. In addition, the current status, potential challenges and future prospects for practical CRT in PD patients will be elaborated as well.

Indexed as

cell replacement therapy (CRT)dopaminergic (DA) neuronsParkinson's Diseasepreparationstem cellstransplantation

Identifiers

PMID27303288
PMCPMC4885841
OpenAlexW2461624812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.